SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Algaba Ferran)
 

Sökning: WFRF:(Algaba Ferran) > Molecular Markers I...

Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups

van Kessel, Kim E. M. (författare)
Erasmus MC, Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands.;Erasmus MC, Erasmus MC Canc Inst, Dept Urol, Rotterdam, Netherlands.
van der Keur, Kirstin A. (författare)
Erasmus MC, Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands.
Dyrskjot, Lars (författare)
Aarhus Univ Hosp, Dept Mol Med, Aarhus, Denmark.
visa fler...
Algaba, Ferran (författare)
Univ Autonoma Barcelona, Fundacio Puigvert, Sect Pathol, Barcelona, Spain.
Welvaart, Naeromy Y. C. (författare)
Erasmus MC, Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands.
Beukers, Willemien (författare)
Erasmus MC, Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands.
Segersten, Ulrika (författare)
Uppsala universitet,Urologkirurgi
Keck, Bastian (författare)
Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Urol, Erlangen, Germany.
Maurer, Tobias (författare)
Tech Univ Munich, Klinikum Rechts Isar, Dept Urol, Munich, Germany.
Simic, Tatjana (författare)
Univ Belgrade, Fac Med, Inst Med & Clin Biochem, Belgrade, Serbia.
Horstmann, Marcus (författare)
Friedrich Schiller Univ Jena, Dept Urol, Jena, Germany.
Grimm, Marc-Oliver (författare)
Friedrich Schiller Univ Jena, Dept Urol, Jena, Germany.
Hermann, Gregers G. (författare)
Univ Copenhagen, Herlev & Gentofte Hosp, Dept Urol, Hellerup, Denmark.
Mogensen, Karin (författare)
Univ Copenhagen, Herlev & Gentofte Hosp, Dept Urol, Hellerup, Denmark.
Hartmann, Arndt (författare)
Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Inst Pathol, Erlangen, Germany.
Harving, Niels (författare)
Aalborg Univ Hosp, Dept Urol, Aalborg, Denmark.
Petersen, Astrid C. (författare)
Aalborg Univ Hosp, Dept Pathol, Aalborg, Denmark.
Jensen, Jorgen B. (författare)
Aarhus Univ Hosp, Dept Urol, Aarhus, Denmark.
Junker, Kerstin (författare)
Saarland Univ, Dept Urol, Homburg, Germany.
Boormans, Joost L. (författare)
Erasmus MC, Erasmus MC Canc Inst, Dept Urol, Rotterdam, Netherlands.
Real, Francisco X. (författare)
CIBERONC, Spanish Natl Canc Res Ctr CNIO, Epithelial Carcinogenesis Grp, Madrid, Spain.;Univ Pompeu Fabra, Dept Expt & Hlth Sci, Barcelona, Spain.
Malats, Nuria (författare)
CIBERONC, Spanish Natl Canc Res Ctr CNIO, Genet & Mol Epidemiol Grp, Madrid, Spain.
Malmström, Per-Uno (författare)
Uppsala universitet,Urologkirurgi
Orntoft, Torben F. (författare)
Aarhus Univ Hosp, Dept Mol Med, Aarhus, Denmark.
Zwarthoff, Ellen C. (författare)
Erasmus MC, Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands.
visa färre...
Erasmus MC, Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands;Erasmus MC, Erasmus MC Canc Inst, Dept Urol, Rotterdam, Netherlands. Erasmus MC, Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands. (creator_code:org_t)
AMER ASSOC CANCER RESEARCH, 2018
2018
Engelska.
Ingår i: Clinical Cancer Research. - : AMER ASSOC CANCER RESEARCH. - 1078-0432 .- 1557-3265. ; 24:7, s. 1586-1593
Relaterad länk:
https://urn.kb.se/re...
visa fler...
https://doi.org/10.1...
visa färre...
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Purpose: The European Association of Urology (EAU) guidelines for non-muscle-invasive bladder cancer (NMIBC) recommend risk stratification based on clinicopathologic parameters. Our aim was to investigate the added value of biomarkers to improve risk stratification of NMIBC. Experimental Design: We prospectively included 1,239 patients in follow-up for NMIBC in six European countries. Fresh-frozen tumor samples were analyzed for GATA2, TBX2, TBX3, and ZIC4 methylation and FGFR3, TERT, PIK3CA, and RAS mutation status. Cox regression analyses identified markers that were significantly associated with progression to muscle-invasive disease. The progression incidence rate (PIR = rate of progression per 100 patient-years) was calculated for subgroups. Results: In our cohort, 276 patients had a low, 273 an intermediate, and 555 a high risk of tumor progression based on the EAU NMIBC guideline. Fifty-seven patients (4.6%) progressed to muscle-invasive disease. The limited number of progressors in this large cohort compared with older studies is likely due to improved treatment in the past two decades. Overall, wild-type FGFR3 and methylation of GATA2 and TBX3 were significantly associated with progression (HR = 0.34, 2.53, and 2.64, respectively). The PIR for EAU high-risk patients was 4.25. On the basis of FGFR3 mutation status and methylation of GATA2, this cohort could be reclassified into a good class (PIR = 0.86, 26.2% of patients), a moderate class (PIR = 4.32, 49.7%), and a poor class (PIR = 7.66, 24.0%). Conclusions: We conclude that the addition of selected biomarkers to the EAU risk stratification increases its accuracy and identifies a subset of NMIBC patients with a very high risk of progression. (C) 2018 AACR.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Urology and Nephrology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy